Viva Biotech Holdings (1873) Stock Statistics & Valuation Metrics

Viva Biotech Holdings has a market cap or net worth of HK$3.07B. The enterprise value is HK$2.88B.

Viva Biotech Holdings has 2,129,882,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Viva Biotech Holdings’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 2.42%.

The current PE Ratio of Viva Biotech Holdings is 18.0. Viva Biotech Holdings’s PEG ratio is 0.69.

In the last 12 months, Viva Biotech Holdings had revenue of 1.73B and earned 219.76M in profits. Earnings per share was 0.10.

In the last 12 months, operating cash flow was 222.02M and capital expenditures -122.05M, giving a free cash flow of 99.97M billion.

Viva Biotech Holdings pays an annual dividend of HK$0.01, resulting in a dividend yield of ―

Viva Biotech Holdings upcoming earnings date is Aug 31, 2026, Before Open (Confirmed).

Viva Biotech Holdings as a current ratio of 1.50, with Debt / Equity ratio of 33.29%

In the past 12 months, Viva Biotech Holdings has paid 48.73M in taxes.

Viva Biotech Holdings EV to EBITDA ratio is 10.82, with an EV/FCF ratio of 47.37.

Viva Biotech Holdings has HK$1.13B in cash and marketable securities with HK$1.33B in debt, giving a net cash position of -HK$199.27M billion.

Gross margin is 37.91%, with operating margin of 11.17%, and net profit margin of 12.71%.

The average price target for Viva Biotech Holdings is HK$4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy